EUVIMEDEUVIMED entdecken
Crossref

Osteoblast-specific 11β-HSD1 overexpression enhances bone mass without inducing systemic side effects

H Lunze, A-K Eiers, J Tuckermann, M Peitzsch, L Hofbauer, M Rauner, U Baschant

Osteologie · 01.05.2026 · 35 (02) · 149-150

DOI: 10.1055/s-0046-1816003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteologie, erschienen am 01.05.2026. Verfasst von H Lunze und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glucocorticoids (GCs) play a central role in regulating inflammation and immune responses and are therefore widely used to treat inflammatory and degenerative bone diseases. However, chronic systemic GC exposure is associated with substantial adverse effects, including impaired bone formation, increased bone resorption, and metabolic disturbances. These limitations underscore the need for strategies that preserve the anti-inflammatory benefits of GCs while minimizing their detrimental systemic impact. Local GC metabolism within the cells is mainly governed by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive GCs into their active forms and thereby amplifies intracellular GC signaling. While excessive systemic GC activity compromises skeletal integrity, targeted modulation of 11β-HSD1 within specific bone cell populations may enhance local GC actions that support bone formation without inducing whole-body side effects.

Methods

Therefore, we generated a mouse model enabling osteoblast-specific enhancement of GC signaling through targeted overexpression of 11β-HSD1. Overexpression was validated at both the gene and protein levels using qPCR and Western blot analyses. Local corticosterone concentrations were quantified by LC/MS to confirm increased GC availability. Bone metabolism and structural changes were assessed using µCT imaging and histological evaluation.

Results

Osteoblast-specific 11β-HSD1 overexpression resulted in increased HSD11B1 expression restricted to osteoblasts, with elevated corticosterone levels detected exclusively in bone (1.5-fold, p 5-fold, p

Zitieren

APA

Lunze, H., Eiers, A., Tuckermann, J., Peitzsch, M., Hofbauer, L., Rauner, M., & Baschant, U. (2026). Osteoblast-specific 11β-HSD1 overexpression enhances bone mass without inducing systemic side effects. Osteologie, 35(02), 149-150. https://doi.org/10.1055/s-0046-1816003

Vancouver

Lunze H, Eiers A, Tuckermann J, Peitzsch M, Hofbauer L, Rauner M, et al. Osteoblast-specific 11β-HSD1 overexpression enhances bone mass without inducing systemic side effects. Osteologie. 2026;35(02):149-150. doi:10.1055/s-0046-1816003

BibTeX
@article{Lunze2026,
  author = {Lunze, H and Eiers, A-K and Tuckermann, J and Peitzsch, M and Hofbauer, L and Rauner, M and Baschant, U},
  title = {Osteoblast-specific 11β-HSD1 overexpression enhances bone mass without inducing systemic side effects},
  journal = {Osteologie},
  year = {2026},
  volume = {35},
  number = {02},
  pages = {149--150},
  doi = {10.1055/s-0046-1816003}
}
Kostenlos starten →